FDA

Five things for pharma marketers to know: Tuesday, May 23, 2017

Five things for pharma marketers to know: Tuesday, May 23, 2017

By

Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug

Five things for pharma marketers to know: Monday, May 22, 2017

Five things for pharma marketers to know: Monday, May 22, 2017

By

Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial

Five things for pharma marketers to know: Wednesday, May 17, 2017

Five things for pharma marketers to know: Wednesday, May 17, 2017

By

FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations

Califf calls for marketers to develop off-label 'code of ethics'

Califf calls for marketers to develop off-label 'code of ethics'

By

The former FDA commissioner said marketers need to focus on ensuring that off-label promotion is "non-misleading."

Five things for pharma marketers to know: Thursday, May 11, 2017

Five things for pharma marketers to know: Thursday, May 11, 2017

By

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

Five things for pharma marketers to know: Wednesday, May 10, 2017

Five things for pharma marketers to know: Wednesday, May 10, 2017

By

The Senate confirms Gottlieb as FDA commissioner; Endo shares DTC plans for Xiaflex; an AstraZeneca asthma drug fails in late-stage study

Five things for pharma marketers to know: Monday, May 1, 2017

Five things for pharma marketers to know: Monday, May 1, 2017

By

The FDA approves osteoporosis drug; groups warn that latest healthcare bill would cut protections for pre-existing conditions; Dupixent gets PBM coverage

Five things for pharma marketers to know: Friday, April 28, 2017

Five things for pharma marketers to know: Friday, April 28, 2017

By

Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective

Five things for pharma marketers to know: Wednesday, April 26, 2017

Five things for pharma marketers to know: Wednesday, April 26, 2017

By

GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products

Five things for pharma marketers to know: Tuesday, April 18, 2017

Five things for pharma marketers to know: Tuesday, April 18, 2017

By

Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals

Five things for pharma marketers to know: Friday, April 7, 2017

Five things for pharma marketers to know: Friday, April 7, 2017

By

The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test

Five things for pharma marketers to know: Thursday, April 6, 2017

Five things for pharma marketers to know: Thursday, April 6, 2017

By

The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers

Five things for pharma marketers to know: Friday, March 24, 2017

Five things for pharma marketers to know: Friday, March 24, 2017

By

Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

By

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

Five things for pharma marketers to know: Monday, March 20, 2017

Five things for pharma marketers to know: Monday, March 20, 2017

By

Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study

Five things for pharma marketers to know: Friday, March 17, 2017

Five things for pharma marketers to know: Friday, March 17, 2017

By

The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

In short, he'll be further along the learning curve than anyone ever tapped for the nation's number-one public health regulatory slot.

Industry groups petition the FDA over off-label rule

Industry groups petition the FDA over off-label rule

By

PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.

Five things for pharma marketers to know: Wednesday, March 15, 2017

Five things for pharma marketers to know: Wednesday, March 15, 2017

By

The FDA considers creating Office of Patient Affairs; Alexion to cut 7% of workforce; FDA committee votes against painkiller's benefits

Five things for pharma marketers to know: Tuesday, March 14, 2017

Five things for pharma marketers to know: Tuesday, March 14, 2017

By

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Five things for pharma marketers to know: Monday, March 6, 2017

Five things for pharma marketers to know: Monday, March 6, 2017

By

Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema

When It Comes to the FDA, Does It All Come Down to Money?

When It Comes to the FDA, Does It All Come Down to Money?

In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?

Five things for pharma marketers to know: Wednesday, March 1, 2017

Five things for pharma marketers to know: Wednesday, March 1, 2017

By

Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported

Why President Trump Won't Overhaul the FDA

Why President Trump Won't Overhaul the FDA

In short, the Trump team, I predict, will seek to tweak FDA.

Is the Trump Administration the Cure the FDA Needs?

Is the Trump Administration the Cure the FDA Needs?

Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.

Five things for pharma marketers to know: Friday, February 24, 2017

Five things for pharma marketers to know: Friday, February 24, 2017

By

PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug

Five things for pharma marketers to know: Thursday, February 16, 2017

Five things for pharma marketers to know: Thursday, February 16, 2017

By

The FDA approves Valeant's psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

By

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Five things for pharma marketers to know: Friday, February 10, 2016

Five things for pharma marketers to know: Friday, February 10, 2016

By

Industry files petition over FDA off-label draft guidance; Marathon secures new DMD drug approval; Price confirmed as head of HHS

Five things for pharma marketers to know: Tuesday, February 7, 2017

Five things for pharma marketers to know: Tuesday, February 7, 2017

By

Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.